RA0142

antibody from Oursmab

Targeting: CLDN1 ILVASC, SEMP1

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0142

Provider

Oursmab

Product name

Lixudebart (Biosimilar Reference Antibody) (CLDN1)

Antibody type

Monoclonal

Description

Lixudebart is a humanized immunoglobulin G1-kappa (IgG1¦Ê) monoclonal antibody that specifically targets the Claudin-1 (CLDN1) protein. As an IgG1 isotype, it is engineered to potentially engage immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC). Claudin-1 is a tight junction protein often dysregulated in certain cancers and liver diseases. By binding to CLDN1, lixudebart is designed to modulate its function, potentially disrupting cancer cell signaling, viability, or intercellular adhesion. It is being investigated as a potential therapeutic agent for CLDN1-expressing cancers, with a particular focus on hepatocellular carcinoma (HCC) and other solid tumors.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.